BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 10775031)

  • 1. Hemostatic abnormalities in patients with thrombotic complications on maintenance hemodialysis.
    Inoue A; Wada H; Takagi M; Yamamuro M; Mukai K; Nakasaki T; Shimura M; Hiyoyama K; Deguchi H; Gabazza EC; Mori Y; Nishikawa M; Deguchi K; Shiku H
    Clin Appl Thromb Hemost; 2000 Apr; 6(2):100-3. PubMed ID: 10775031
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased tissue factor pathway inhibitor in patients with acute myocardial infarction.
    Kamikura Y; Wada H; Yamada A; Shimura M; Hiyoyama K; Shiku H; Tanigawa M; Nishikawa H; Yamada N; Isaka N; Nakano T; Kumeda K; Kato H
    Am J Hematol; 1997 Aug; 55(4):183-7. PubMed ID: 9257877
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Poor outcome in disseminated intravascular coagulation or thrombotic thrombocytopenic purpura patients with severe vascular endothelial cell injuries.
    Wada H; Mori Y; Shimura M; Hiyoyama K; Ioka M; Nakasaki T; Nishikawa M; Nakano M; Kumeda K; Kaneko T; Nakamura S; Shiku H
    Am J Hematol; 1998 Jul; 58(3):189-94. PubMed ID: 9662269
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aberrations of the tissue factor pathway in patients positive for lupus anticoagulant.
    Wakita Y; Wada H; Nakase T; Nakasaki T; Shimura M; Hiyoyama K; Mori Y; Gabazza EC; Nishikawa M; Deguchi K; Shiku H
    Clin Appl Thromb Hemost; 1999 Jan; 5(1):10-5. PubMed ID: 10725976
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hemostatic molecular markers before the onset of disseminated intravascular coagulation.
    Wada H; Sakuragawa N; Mori Y; Takagi M; Nakasaki T; Shimura M; Hiyoyama K; Nisikawa M; Gabazza EC; Deguchi K; Kazama M; Shiku H
    Am J Hematol; 1999 Apr; 60(4):273-8. PubMed ID: 10203100
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased activated protein C: protein C inhibitor complex and decreased protein C inhibitor levels in patients with chronic renal failure on maintenance hemodialysis.
    Takagi M; Wada H; Mukai K; Minamikawa K; Wakita Y; Deguchi K; Junji N; Hayashi T; Suzuki K; Shiku H
    Clin Appl Thromb Hemost; 1999 Apr; 5(2):113-6. PubMed ID: 10725991
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased hemostatic molecular markers in patients undergoing anticoagulant therapy.
    Wada H; Ikuma H; Mori Y; Shimura M; Hiyoyama K; Nakasaki T; Onoda K; Yamada N; Ohta T; Nishioka J; Sakuragawa N; Shiku H
    Semin Thromb Hemost; 2000; 26(1):113-8. PubMed ID: 10805292
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma levels of total plasminogen activator inhibitor-I (PAI-I) and tPA/PAI-1 complex in patients with disseminated intravascular coagulation and thrombotic thrombocytopenic purpura.
    Watanabe R; Wada H; Miura Y; Murata Y; Watanabe Y; Sakakura M; Okugawa Y; Nakasaki T; Mori Y; Nishikawa M; Gabazza EC; Shiku H; Nobori T
    Clin Appl Thromb Hemost; 2001 Jul; 7(3):229-33. PubMed ID: 11441985
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The clinical significance of TAT, PIC, TM, and t-PAIC in vascular events of BCR/ABL-negative myeloproliferative neoplasms.
    Huang K; Mo Q; Liao C; Feng S; Liu G; Jiang D; Lei P
    Clin Exp Med; 2024 May; 24(1):107. PubMed ID: 38776019
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High plasma fibrinogen level is associated with poor clinical outcome in DIC patients.
    Wada H; Mori Y; Okabayashi K; Gabazza EC; Kushiya F; Watanabe M; Nishikawa M; Shiku H; Nobori T
    Am J Hematol; 2003 Jan; 72(1):1-7. PubMed ID: 12508260
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changes of plasma hemostatic markers during percutaneous transluminal coronary angioplasty in patients with chronic coronary artery disease.
    Saito Y; Wada H; Yamamuro M; Inoue A; Shimura M; Hiyoyama K; Gabazza EC; Isaka N; Shiku H; Takeya H; Suzuki K; Kumeda K; Kato H; Nakano T
    Am J Hematol; 1999 Aug; 61(4):238-42. PubMed ID: 10440909
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma levels of activated protein C-protein C inhibitor complex in patients with hypercoagulable states.
    Watanabe R; Wada H; Sakakura M; Mori Y; Nakasaki T; Okugawa Y; Gabazza EC; Hayashi T; Nishioka J; Suzuki K; Shiku H; Nobori T
    Am J Hematol; 2000 Sep; 65(1):35-40. PubMed ID: 10936861
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnosis of disseminated intravascular coagulation by hemostatic molecular markers.
    Wada H; Gabazza E; Nakasaki T; Shimura M; Hiyoyama K; Deguchi K; Nishikawa M; Sakuragawa N; Shiku H
    Semin Thromb Hemost; 2000; 26(1):17-21. PubMed ID: 10805276
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Circulating thrombomodulin and hematological alterations in type 2 diabetic patients with retinopathy.
    Fujiwara Y; Tagami S; Kawakami Y
    J Atheroscler Thromb; 1998; 5(1):21-8. PubMed ID: 10077454
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Age-based difference in activation markers of coagulation and fibrinolysis in extracorporeal membrane oxygenation.
    Hundalani SG; Nguyen KT; Soundar E; Kostousov V; Bomgaars L; Moise A; Hui SK; Teruya J
    Pediatr Crit Care Med; 2014 Jun; 15(5):e198-205. PubMed ID: 24614609
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnostic and Prognostic Value of TAT, PIC, TM, and t-PAIC in Malignant Tumor Patients With Venous Thrombosis.
    Zhou K; Zhang J; Zheng ZR; Zhou YZ; Zhou X; Wang LD; Suo B; Jiang XF; Liu PJ; Wang DH
    Clin Appl Thromb Hemost; 2020; 26():1076029620971041. PubMed ID: 33141604
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluating prethrombotic state in lung cancer using molecular markers.
    Gabazza EC; Taguchi O; Yamakami T; Machishi M; Ibata H; Suzuki S
    Chest; 1993 Jan; 103(1):196-200. PubMed ID: 7678080
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Studies on molecular markers for hemostasis and thrombosis in various renal diseases].
    Shibata T; Ishii T; Tomo T; Kaneko K; Nasu M; Magari Y; Fukushima K
    Nihon Jinzo Gakkai Shi; 1991 Apr; 33(4):373-8. PubMed ID: 1831516
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Good or poor responses of hemostatic molecular markers in patients with hematopoietic disorders after treatment of disseminated intravascular coagulation.
    Watanabe R; Wada H; Yamamuro M; Inoue A; Watanabe M; Kumeda K; Sakakura M; Okugawa Y; Nakasaki T; Deguchi H; Gabazza EC; Mori Y; Nishikawa M; Nobori T; Shiku H
    Clin Appl Thromb Hemost; 2003 Jan; 9(1):71-7. PubMed ID: 12643327
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Coagulation and fibrinolysis factors in dialysis patients with and without ischemic heart disease.
    Oda H; Ohno M; Ohashi H
    Adv Perit Dial; 2000; 16():152-5. PubMed ID: 11045282
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.